Side by side: size, value over time, results, valuation, margins, growth, debt and shareholder returns, and any of thirty figures charted over the years (up to 6).
Open these as a peer group: up to 12 companies with suggested peers, each company's rank in the group and percentile in its sector and country, saved for you or your team.
US$ billions, as reported in each year's annual results.
Operating income as a share of revenue. US dollars at each year's exchange rate.
| Measure | Alector, Inc.✕ ALEC · #14,879 in the world |
|---|---|
| Profile | |
| Country | 🇺🇸 USA |
| Sector | Healthcare |
| Industry | Biotechnology |
| Founded | — |
| Size | |
| Market cap | $293 M |
| Net income | $-143 M |
| Employees | |
The largest companies, each against its nearest peers in value from the same industry.
| Fiscal year | Alector, Inc. |
|---|---|
| 2024 | -144.2%SEC |
| 2023 | -156.3%SEC |
| 2022 | -103.2%SEC |
| 2021 | -18.0%SEC |
| 2020 | -925.0%SEC |
| 2019 | -539.1%SEC |
| 2018 | -207.0%SEC |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports; Ed. = the company's report (editors); WD = Wikidata, citing the annual report; Cap = value.today market caps. Hover a figure for its period.
| 185 |
| Valuation | |
|---|---|
| Price to book | 9.6× |
| Free cash flow yield | -62.8% |
| Profitability | |
|---|---|
| Return on equity | -181.6% |
| Financial strength | |
|---|---|
| Debt to equity | 0.3× |
| Altman Z-score zone | — |
|---|
| Data as of | Market cap Oct 2026; ratios FY2025 |
|---|
Market caps from exchange data or SEC filings on the date shown (* last known value, no current one); revenue and net income from the latest annual results; ratios worked out from each company's own statements for the fiscal year shown. ▲ marks the best of these companies where higher or lower is better; size and valuation multiples are marked for no one. Definitions: methodology.